Prelude Therapeutics Advances KAT6A Degrader PRT13722 Toward Clinical Trials
Event summary
- Prelude Therapeutics' preclinical abstract for PRT13722, a first-in-class oral KAT6A selective degrader, accepted for 2026 AACR Annual Meeting.
- Poster presentation scheduled for April 21, 2026, detailing monotherapy tumor regressions and improved hematological safety profile.
- IND filing expected mid-2026 with Phase 1 trials planned for second half of 2026.
- Prelude's Director of Biology to present on targeted protein degrader-antibody conjugates (DACs) on April 18, 2026.
The big picture
Prelude's progress with PRT13722 reflects the growing emphasis on selective protein degradation in oncology. The company's focus on KAT6A targeting positions it in a competitive but emerging space for ER+ breast cancer treatments. Success here could validate Prelude's platform approach to targeted degraders and DACs, potentially attracting partnership interest.
What we're watching
- Clinical Timelines
- Whether Prelude can maintain its aggressive IND filing and Phase 1 trial schedule through mid-2026.
- Therapeutic Differentiation
- How PRT13722's selective degradation profile will position it against broader KAT6 inhibitors in ER+ breast cancer.
- Combination Therapy Potential
- The pace at which Prelude can demonstrate PRT13722's combinability with standard of care agents.